Navigation Links
Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Date:3/25/2011

ual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, ; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Fentora® is a registered trademark of Cima Labs, Inc., a subsidiary of Cephalon, Inc..

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:
Patty Eisenhaur
Watson Pharmaceuticals, Inc.
(973) 355-8141

Media:
Charlie Mayr
Watson Pharmaceuticals, Inc.
(973) 355-8483


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Watson Launches Generic Famvir®
3. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
6. Watson to Present at the Barclays 2011 Global Healthcare Conference
7. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
8. Watson to Present at the 2011 Citi Global Healthcare Conference
9. Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million
10. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
11. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)...  Eli Lilly and Company (NYSE: ... study in genetically engineered mice examining combination therapy ... N3pG and beta-secretase inhibitor BACE (LY2811376). Data results ... removing clumps of amyloid-beta protein in the brain ... to Alzheimer,s disease (AD) – than use of ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "Global and Chinese Medical X-ray Film Industry ... http://photos.prnewswire.com/prnh/20130307/600769 Global And ... professional and in-depth study on the current state of ... on the Chinese situation. The report provides a ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... with management to discuss first quarter 2011 financial results, as ... 4, 2011, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... first quarter ended March 31, 2011 will be released earlier ...
... iMD Companies (ICBU.PK) is pleased to announce that is ... Mobile Imaging LLC, which increases and diversifies the Company,s ... with cash and restricted stock and is accretive to ... www.OMIAZ.com .   OMI is currently running at ...
Cached Medicine Technology:Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast 2iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 2iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 3
(Date:7/13/2014)... 2014 Micro irrigation systems are mainly ... dispersal as wells as to maintain soil quality. The ... to become a dominant revenue generator for manufacturers in ... reduce resource costs has led to the adoption of ... has further caused massive demand for micro irrigation systems, ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... LOVELAND, Colo., Dec. 3 Heska Corporation,(Nasdaq: ... the BioWest 2007 Mature,Company Forum on December 6, ... in Denver, Colorado. The presentation is scheduled to ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), About Heska, Heska Corporation ...
... UCB today announced data demonstrating,that anti-epileptic ... name,Rikelta(TM), administered as an adjunctive treatment in ... significantly reduced,seizure frequency and had a side-effect ... two Phase IIb (Abstracts C.04 and 3.218), ...
... SAN FRANCISCO, Calif., Dec. 3 Exelixis,Inc. (Nasdaq: EXEL ... and,investor briefing in conjunction with The American Society of Hematology,48th ... Monday, December 10,2007., The event will be webcast and ... http://www.exelixis.com ., Speakers:, -- Michael Morrissey, ...
... ORLANDO, Fla., Dec. 3 A new study ... depressant effects in,patients (40 years and older) with ... measured by oxygenation or abnormal breathing,events relative to ... at the 53rd International,Respiratory Congress of the American ...
... In the first survey to specifically measure hospital ... Institute (LA BioMed) researchers found few U.S. emergency rooms ... Drs. Marianne Gausche-Hill, Charles Schmitz and Roger J. Lewis ... peer-reviewed journal of the American Academy of Pediatrics. The ...
... 2007 Psychiatry researchers at Washington University School of Medicine ... alcohol dependence in young adults is associated with having a ... study reported 50 or 100 partners, and research shows ... partners you have, the more likely you,ll encounter someone with ...
Cached Medicine News:Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 2Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 3Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 4Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 5Health News:Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting 2Health News:New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD 2Health News:New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD 3Health News:New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD 4Health News:LA BioMed researchers find few emergency rooms fully equipped for pediatric patients 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 3
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... PARI TREK™ Compact Compressor is for active ... treatments anywhere and everywhere. The compressor is ... power source optionsworldwide AC compatibility (100 to ... permit patients the freedom to take aerosol ...
Medicine Products: